BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:“EGFR Mutation Screening in NSCLC” - Dr David Gonzalez de Cast
 ro\, The Institute of Cancer Research and Royal Marsden Hospital
DTSTART:20100928T110000Z
DTEND:20100928T120000Z
UID:TALK25985@talks.cam.ac.uk
CONTACT:Mala Jayasundera
DESCRIPTION:"According to the new NICE guidance for non-small cell lung ca
 ncers (NSCLC)\, EGFR mutations must now be routinely screened for all newl
 y diagnosed patients with local advanced disease to assess whether they ar
 e eligible for first-line targeted treatment with the tyrosine kinase inhi
 bitor gefitinib. Recent results from phase III trials have shown a selecti
 ve response to TKi for those NSCLC patients carrying EGFR mutations\, as w
 ell as a significant improvement in progression-free survival. These resul
 ts represent one of the major advances in the treatment of NSCLC in decade
 s and it is one of the best examples we currently have for Personalised Ca
 ncer Medicine. However\, implementation of EGFR mutation screening within 
 the clinical diagnostic setting presents certain challenge\, including the
  quality of the samples\, tissue types\, methodology used\, etc. as well a
 s the turnaround times and integration of the mutation data in the multidi
 sciplinary team (MDTs) approach to diagnosis in the UK. These challenges a
 nd the practical and clinical implications of EGFR mutation testing will b
 e addressed during the presentation."
LOCATION:CRI Lecture Theatre
END:VEVENT
END:VCALENDAR